What are the recommended admission orders for a patient with non‑ST‑segment elevation myocardial infarction (NSTEMI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

NSTEMI Admission Orders

Admit all NSTEMI patients to a monitored unit with continuous cardiac rhythm monitoring, initiate dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor (preferably ticagrelor or prasugrel), start parenteral anticoagulation, and obtain serial high-sensitivity troponins with ECG monitoring. 1, 2

Immediate Admission Requirements

Monitoring and Location

  • Admit to monitored unit (CCU/step-down) with continuous telemetry 1
  • Continue rhythm monitoring minimum 24 hours or until PCI, whichever comes first, for low-risk patients 1
  • Extend monitoring beyond 24 hours for patients at increased arrhythmia risk 1

Diagnostic Testing on Admission

ECG:

  • Obtain 12-lead ECG immediately
  • Repeat ECG with any recurrent symptoms or if initial diagnosis uncertain 1
  • Consider additional leads (V3R, V4R, V7-V9) if standard leads inconclusive and ongoing ischemia suspected 1

Cardiac Biomarkers:

  • Serial high-sensitivity troponin measurements using 0h/1h algorithm (preferred) or 0h/2h algorithm 1
  • If first two measurements inconclusive but clinical suspicion remains high, obtain additional testing at 3 hours 1
  • Continue serial troponins for prognostic stratification 1

Echocardiography:

  • Order transthoracic echo to evaluate LV function, regional wall motion abnormalities, and exclude differential diagnoses 1
  • Perform immediately if hemodynamic instability or cardiac arrest 1

Antiplatelet Therapy Orders

Aspirin (for all patients without contraindications)

  • Loading dose: 150-300 mg PO (or 75-250 mg IV) 1
  • Maintenance: 75-100 mg daily (use 81 mg daily if combined with ticagrelor) 1, 2

P2Y12 Inhibitor (choose one based on patient factors)

First-line options:

  • Ticagrelor (preferred for most patients, regardless of invasive vs conservative strategy):

    • Loading: 180 mg PO
    • Maintenance: 90 mg twice daily
    • Continue for 12 months 1, 2
  • Prasugrel (for P2Y12-naïve patients proceeding to PCI):

    • Loading: 60 mg PO
    • Maintenance: 10 mg daily (reduce to 5 mg daily if age ≥75 years or weight <60 kg)
    • Continue for 12 months 1
  • Clopidogrel (only if prasugrel/ticagrelor unavailable, not tolerated, or contraindicated):

    • Loading: 300-600 mg PO
    • Maintenance: 75 mg daily 1

Critical caveat: Do NOT routinely pre-treat with P2Y12 inhibitor if coronary anatomy unknown and early invasive management planned 1

Anticoagulation Orders (choose one)

Parenteral anticoagulation required for all patients in addition to antiplatelet therapy 1, 2

Preferred options:

  • Enoxaparin: 1 mg/kg SC every 12 hours (reduce to 1 mg/kg once daily if CrCl <30 mL/min); may give 30 mg IV loading dose; continue until PCI or hospital discharge 2

  • Fondaparinux: 2.5 mg SC daily; continue until PCI or discharge 2

    • Must add UFH or bivalirudin during PCI to prevent catheter thrombosis 2
  • UFH: 60 IU/kg IV bolus (max 4000 IU), then 12 IU/kg/hour infusion (max 1000 IU/hour); adjust per aPTT per hospital protocol; continue 48 hours or until PCI 2

  • Bivalirudin: 0.10 mg/kg loading dose, then 0.25 mg/kg/hour (only for early invasive strategy); continue until angiography/PCI 2

Additional Admission Orders

Anti-ischemic Therapy

  • Nitroglycerin sublingual 0.4 mg PRN chest pain (hold if systolic BP <90 mmHg)
  • Consider IV nitroglycerin if ongoing ischemia
  • Beta-blocker (if no contraindications): metoprolol 25-50 mg PO every 6-12 hours or equivalent
  • High-intensity statin: atorvastatin 80 mg daily or rosuvastatin 40 mg daily

Supportive Care

  • Oxygen only if SpO2 <90% (avoid routine supplemental oxygen)
  • NPO after midnight if early invasive strategy planned
  • IV access with normal saline at KVO rate
  • Strict bed rest initially, then progressive activity as tolerated

Laboratory Orders

  • Complete metabolic panel, CBC, lipid panel, HbA1c
  • Type and screen
  • BNP or NT-proBNP for risk stratification (optional but reasonable)

Contraindications to Note

Do NOT order:

  • GP IIb/IIIa inhibitors routinely (only consider for high-risk features during PCI) 1, 2
  • IV fibrinolytic therapy (Class III Harm) 2
  • Additional biomarkers beyond hs-troponin for routine diagnosis (h-FABP, copeptin) 1

Risk Stratification for Timing of Angiography

Determine urgency of invasive strategy based on clinical presentation:

  • Urgent/immediate (<2 hours): Refractory angina, hemodynamic instability, electrical instability, cardiogenic shock
  • **Early invasive (<24 hours):** High-risk features (elevated troponin, dynamic ECG changes, GRACE score >140)
  • Ischemia-guided (selective): Low-risk patients without high-risk features

The 2021 ESC guidelines 1 and 2014 AHA/ACC guidelines 2 provide the framework for these admission orders, with emphasis on immediate dual antiplatelet therapy, anticoagulation, and monitored setting to reduce mortality and recurrent ischemic events.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.